Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ43UK
|
|||
| Drug Name |
ALXN2040
|
|||
| Synonyms |
Danicopan
Click to Show/Hide
|
|||
| Indication | Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0; ICD-10: D59.5] | Phase 3 | [1] | |
| Company |
Alexion AstraZeneca Rare Disease
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor D (CFD) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Platelet degranulation | |||
| Alternative complement activation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Adipogenesis | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04469465) A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH). U.S.National Institutes of Health. | |||
| REF 2 | Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1;106(12):3188-3197. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.